FDA Approves Amneal’s Generic Suboxone to Treat Opioid Drug Dependence

Amneal Pharmaceuticals, LLC, the 7th largest generic drug manufacturer in the U.S. market, has received U.S. FDA approval for one of the first generic versions of Suboxone® sublingual tablets for maintenance treatment of opioid drug dependence. Generic buprenorphine hydrochloride (HCl) and naloxone HCl dihydrate sublingual tablets are now available in 2 mg/0.5 mg and 8 mg/2 mg strengths, both in 30-count bottles. 


Source: NewsMedical.net – February 25, 2013

Note: On February 26, 2013 the FDA also approved Actavis’ generic Suboxone for treatment of opioid dependence. 


Source: NewsMedical.net – February 26, 2013